“Joseph brings an outstanding combination of experience, client focus and industry knowledge. His leadership and commitment to delivering innovative solutions to the industry’s most complex problems continues to propel our clients’ and the firm’s growth.” said Matt Riordan, Partner & Boston Office Head. “We are excited to share in this career milestone with him and look forward to his future success with the firm.”
Joseph serves leading biopharmaceutical and early stage life-science companies, developing strategies for pipeline products and portfolios, evaluating commercial opportunities, modeling detailed patient flows and treatment pathways, and optimizing plans for development, launch, and life-cycle management. Joseph has been foundational in developing the firm’s industry leading practice in cell, gene and tissue therapies. His clients span a wide range of therapeutic areas, with particular focus on hematology / oncology and neurology, as well as novel technologies. Leveraging his experience across pipeline and established products, common and rare diseases, and US and global markets, Joseph draws upon a diverse problem-solving toolkit to add breadth and depth to his clients’ strategic analysis and planning. Joseph earned his PhD in Biomedical Engineering from Harvard-MIT, where he specialized in neurophysiology. He earned a Masters of Advanced Study in Mathematics from Cambridge University and graduated magna cum laude from Harvard University with a degree in Physics and Philosophy.